A drug combination of artemisinin-naphthoquine should be considered for the treatment of children with uncomplicated malaria in settings where multiple parasite species cause malaria according to Tim Davis from University of Western Australia, Fremantle, Australia and colleagues in new research published in this week's PLOS Medicine.
Malaria is a mosquito-borne parasitic disease that kills approximately 600,000 people every year. Several different parasite species cause malaria and in some settings, such as Papua New Guinea, two species, Plasmodium falciparum and Plasmodium vivax, are responsible for the majority of malaria infections. However, the two species respond differently to currently available anti-malarial drugs.
The authors compared the current recommended therapy for uncomplicated malaria in children in Papua New Guinea, artemether-lumefantrine, with a different combination therapy, artemisinin-naphthoquine. Using a randomized, controlled trial study design including 186 children with Plasmodium falciparum infections and 47 children with Plasmodium vivax infections, the researchers found that artemisinin-naphthoquine was non-inferior to artemether-lumefantrine for treating Plasmodium falciparum (a difference of 2.2% for reappearance of infection within 42 days) but was more effective for treating Plasmodium vivax (a difference of 70.0% for reappearance of infection within 42 days).
The authors conclude, "The efficacy, tolerability, and safety of three daily doses of artemisinin-naphthoquine suggest that this regimen should be considered together with other currently available effective [artemisinin combination therapies] for treatment of uncomplicated malaria in [Papua New Guinea] and similar epidemiologic settings with transmission of multiple Plasmodium species."
Reference: Laman M, Moore BR, Benjamin JM, Yadi G, Bona C, et al. (2014) Artemisinin-Naphthoquine versus Artemether-Lumefantrine for Uncomplicated Malaria in Papua New Guinean Children: An Open-Label Randomized Trial. PLoS Med 11(12): e1001773. doi:10.1371/journal.pmed.1001773
Source: University of Western Australia
Beyond the Surface: Rethinking Environmental Hygiene Validation at Exchange25
June 30th 2025Environmental hygiene is about more than just shiny surfaces. At Exchange25, infection prevention experts urged the field to look deeper, rethink blame, and validate cleaning efforts across the entire care environment, not just EVS tasks.
A Controversial Reboot: New Vaccine Panel Faces Scrutiny, Support, and Sharp Divides
June 26th 2025As the newly appointed Advisory Committee on Immunization Practices (ACIP) met for the first time under sweeping changes by HHS Secretary Robert F. Kennedy Jr, the national spotlight turned to the panel’s legitimacy, vaccine guidance, and whether science or ideology would steer public health policy in a polarized era.
Getting Down and Dirty With PPE: Presentations at HSPA by Jill Holdsworth and Katie Belski
June 26th 2025In the heart of the hospital, decontamination technicians tackle one of health care’s dirtiest—and most vital—jobs. At HSPA 2025, 6 packed workshops led by experts Jill Holdsworth and Katie Belski spotlighted the crucial, often-overlooked art of PPE removal. The message was clear: proper doffing saves lives, starting with your own.